Publication | Open Access

Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: A randomized, double-blind, placebo-controlled trial

Autoimmune DiseaseNeurological DisorderImmunologyNeurological ProgressAutoimmunityPlacebo-controlled TrialNeurologyMultiple SclerosisIntravenous Immunoglobulin TreatmentImmunotherapyMedicineNeuroimmunology